Several molecular changes have been identified in IBC, including loss of WNT1-inducible signaling pathway protein-3 (WISP3) and overexpression of Rho GTPase [6], E-cadherin [7], angiogenic factors [8], translation initiation factor eIF4GI [9], and tazarotene-induced gene 1 (TIG1) [10]. The gene discussed is CDH1; the disease is inflammatory breast carcinoma.